Retrospective control study evaluated the clinical impact of TUEB in 251 patients divided into two groups of ≥ 80 mL and >80 mL.
Enucleation efficiency, PSA reduction, catheterization
Enucleation efficiency was better at 0.71 g/min in large PV group vs. 0.97 g/min in small PV group, p<0.001.
PSA reduction was greater at ~1.74 ng/mL in large PV group vs. ~1.52 ng/mL in small PV group, p=0.008.
Catheterization time was shorter with 2.73 days in large PV group vs. 2.91 days in small PV group.
IPSS, QoL, Qmax, PVR scores at 3 months:
Significant improvements in both groups compared to baseline.
Similar differences were maintained at 6 and 12 months.
Further benefits
Surgeons may find TUEB less challenging in large BPH cases.
TUEB using TUEB loop was easy, and no power was required to peel/push adenoma because of spatula attached to loop.
90% of large PV patients did not require BPH intervention up to 3 years of follow-up.
TUEB using TUEB loop provides high satisfaction regarding the enucleation efficiency, efficacy and safety and can be one of the best treatments for large BPH.
Alfoo-Improved Pharmacokinetics
ALFOO, containing Alfuzosin molecule, is Anti-BPH which helps in treatment of LUTS due to BPH in Young Sexually Active Male in 40-60 year old age group
